Business Description
ProPhase Labs Inc
NAICS : 541380
SIC : 8734
ISIN : US74345W1080
Total Employee Number:
96Description
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -0.01 | |||||
Debt-to-Equity | -14.51 | |||||
Debt-to-EBITDA | -1.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.76 | |||||
Beneish M-Score | -4.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -80.2 | |||||
3-Year Book Growth Rate | -78.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.95 | |||||
9-Day RSI | 39.33 | |||||
14-Day RSI | 41.67 | |||||
3-1 Month Momentum % | 58.1 | |||||
6-1 Month Momentum % | -62.15 | |||||
12-1 Month Momentum % | -96.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.06 | |||||
Quick Ratio | 0.05 | |||||
Days Inventory | 73.43 | |||||
Days Sales Outstanding | 1026.02 | |||||
Days Payable | 2149.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -76.9 | |||||
Shareholder Yield % | 1386.75 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 30.22 | |||||
Operating Margin % | -500.86 | |||||
Net Margin % | -709.4 | |||||
EBITDA Margin % | -241.42 | |||||
FCF Margin % | -168.37 | |||||
OCF Margin % | -168.37 | |||||
ROE % | -331.36 | |||||
ROA % | -43.52 | |||||
ROIC % | -31.72 | |||||
3-Year ROIIC % | -400.05 | |||||
ROC (Joel Greenblatt) % | -252.1 | |||||
ROCE % | -125.55 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.01 | |||||
PS Ratio | 0.12 | |||||
EV-to-EBIT | -0.64 | |||||
EV-to-Forward-EBIT | 10.22 | |||||
EV-to-EBITDA | -1.22 | |||||
EV-to-Revenue | 2.94 | |||||
EV-to-Forward-Revenue | 1.32 | |||||
EV-to-FCF | -1.75 | |||||
Price-to-GF-Value | 0.09 | |||||
Earnings Yield (Greenblatt) % | -156.25 | |||||
FCF Yield % | -522.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PRPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProPhase Labs Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.392 | ||
| EPS (TTM) ($) | -3.955 | ||
| Beta | 1.5312 | ||
| 3-Year Sharpe Ratio | -1.21 | ||
| 3-Year Sortino Ratio | -1.35 | ||
| Volatility % | 125.17 | ||
| 14-Day RSI | 41.67 | ||
| 14-Day ATR ($) | 0.018671 | ||
| 20-Day SMA ($) | 0.091496 | ||
| 12-1 Month Momentum % | -96.6 | ||
| 52-Week Range ($) | 0.068 - 6.659 | ||
| Shares Outstanding (Mil) | 14.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProPhase Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProPhase Labs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-19 14:00 | In 138 days | ||
| Third quarter earnings results for 2026 | 2026-11-19 | In 137 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 14:00 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 39 days | ||
| General meeting for 2026 | 2026-07-17 16:00 | In 13 days | ||
| First quarter earnings conference call for 2026 | 2026-07-08 | In 3 days | ||
| First quarter earnings results for 2026 | 2026-06-30 | 0.09 (+3.36%) | ||
| Annual report for 2025 | 2026-06-01 | 0.10 (+16.57%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-15 | 0.14 (+0.00%) | ||
| 0.1:1 Stock Split | 2025-12-22 | 0.90 (-50.82%) |
Show
Entries
ProPhase Labs Inc Frequently Asked Questions
What is ProPhase Labs Inc(PRPH)'s stock price today?
The current price of PRPH is $0.08. The 52 week high of PRPH is $6.66 and 52 week low is $0.07.
When is next earnings date of ProPhase Labs Inc(PRPH)?
The next earnings date of ProPhase Labs Inc(PRPH) is 2026-08-13 Est..
Does ProPhase Labs Inc(PRPH) pay dividends? If so, how much?
ProPhase Labs Inc(PRPH) does not pay dividend.
Guru Commentaries on OTCPK:PRPH
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ProPhase Labs Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers